title: Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
abstract: Spontaneous pyopneumothorax is a very rare occurrence, even in cancer treated patients. Here we present two consecutive cases of spontaneous pyopneumothorax that occurred early after initiation of mTOR inhibitors for the treatment of renal cell carcinoma with subpleural pulmonary metastasis. In these two cases, necrosis and excavation of lung metastasis were observed, suggesting their involvement in the pathogenic mechanism of pyopneumothorax. This report extends the available experience of the pulmonary side effects of these novel targeted therapies.
authors.affiliation: Department of Medical Oncology, Centre Georges François Leclerc, 1 rue du Professeur Marion, 21000, Dijon, France. sladoire@dijon.fnclcc.fr
authors.forename: Sylvain
authors.initials: S
authors.lastname: Ladoire
authors.forename: Caroline
authors.initials: C
authors.lastname: Beynat
authors.forename: Pierre
authors.initials: P
authors.lastname: Diaz
authors.forename: Bruno
authors.initials: B
authors.lastname: Coudert
authors.forename: Laure
authors.initials: L
authors.lastname: Favier
authors.forename: François
authors.initials: F
authors.lastname: Ghiringhelli
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000008:administration & dosage; D002116:Calcitonin / Q000097:blood; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D003131:Combined Modality Therapy; D004198:Disease Susceptibility; D000068338:Everolimus; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D008175:Lung Neoplasms / Q000150:complications / Q000188:drug therapy / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D009392:Nephrectomy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D018410:Pneumonia, Bacterial / Q000150:complications; D011030:Pneumothorax / Q000139:chemically induced*; D011498:Protein Precursors / Q000097:blood; D011725:Pyridines / Q000008:administration & dosage; D011758:Pyrroles / Q000008:administration & dosage; D012422:Rupture, Spontaneous; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077157:Sorafenib; D000077210:Sunitinib; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D001557:Benzenesulfonates; D007211:Indoles; D009363:Neoplasm Proteins; D010671:Phenylurea Compounds; D011498:Protein Precursors; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; C401859:temsirolimus; D002116:Calcitonin; D000068338:Everolimus; D000077157:Sorafenib; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D000077210:Sunitinib; D020123:Sirolimus